Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens
Acurx Pharmaceuticals, Inc. (ACXP)
Company Research
Source: PR Newswire
DNA polymerase (pol) IIIC inhibitors are an innovative new class of antibiotics, the first in more than 30 years, that target a critical enzyme of Gram-positive bacteria including C. difficile, MRSA, VRE and PRSP (penicillin-resistant Streptococcus pneumonia) Acurx's lead DNA pol IIIC antibiotic, ibezapolstat (IBZ), has clinically validated this bacterial target by demonstrating Phase 2 efficacy in the treatment of C. difficile Infection, showing 96% initial cure and no recurrence of infection, and is now Phase 3 ready in the U.S. and in the EU The Company's preclinical pipeline of DNA pol IIIC antibiotics includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections) and Hospital/Ventilator-Acquired Pneumonia (HAP/VAP), upon which a development program for treatment of inhaled anthrax is being planned in parallel The CDC classifies C. di
Show less
Read more
Impact Snapshot
Event Time:
ACXP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACXP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACXP alerts
High impacting Acurx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ACXP
News
- Acurx Pharmaceuticals (NASDAQ:ACXP) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ACXP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx PharmaceuticalsPR Newswire
- New to The Street Airs Landmark Show #700 Today at 6:30 PM ET on Bloomberg Television [Yahoo! Finance]Yahoo! Finance
- Acurx Pharmaceuticals GAAP EPS of -$1.23 beats by $0.05 [Seeking Alpha]Seeking Alpha
- Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business UpdatePR Newswire
ACXP
Earnings
- 11/12/25 - Beat
ACXP
Analyst Actions
- 9/30/25 - HC Wainwright
ACXP
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form 10-Q
- 11/10/25 - Form 424B3
- ACXP's page on the SEC website